These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 17982881)

  • 1. Animal models in neurodegenerative diseases.
    Hirsch EC
    J Neural Transm Suppl; 2007; (72):87-90. PubMed ID: 17982881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How to judge animal models of Parkinson's disease in terms of neuroprotection.
    Hirsch EC
    J Neural Transm Suppl; 2006; (70):255-60. PubMed ID: 17017538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Back and to the Future: From Neurotoxin-Induced to Human Parkinson's Disease Models.
    Airavaara M; Parkkinen I; Konovalova J; Albert K; Chmielarz P; Domanskyi A
    Curr Protoc Neurosci; 2020 Mar; 91(1):e88. PubMed ID: 32049438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. alpha-synuclein and Parkinson's disease: the first roadblock.
    Chua CE; Tang BL
    J Cell Mol Med; 2006; 10(4):837-46. PubMed ID: 17125588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
    Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
    Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
    Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
    Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson's Disease.
    Nuber S; Rajsombath M; Minakaki G; Winkler J; Müller CP; Ericsson M; Caldarone B; Dettmer U; Selkoe DJ
    Neuron; 2018 Oct; 100(1):75-90.e5. PubMed ID: 30308173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease.
    Auluck PK; Chan HY; Trojanowski JQ; Lee VM; Bonini NM
    Science; 2002 Feb; 295(5556):865-8. PubMed ID: 11823645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of genetic models in understanding the cause and mechanisms of Parkinson's disease.
    Moore DJ; Dawson TM
    Curr Neurol Neurosci Rep; 2008 Jul; 8(4):288-96. PubMed ID: 18590612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?
    Volpicelli-Daley LA; Kirik D; Stoyka LE; Standaert DG; Harms AS
    J Neurochem; 2016 Oct; 139 Suppl 1(Suppl 1):131-155. PubMed ID: 27018978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Astrocytes in Parkinson's Disease Associated with Genetic Mutations and Neurotoxicants.
    Kim S; Pajarillo E; Nyarko-Danquah I; Aschner M; Lee E
    Cells; 2023 Feb; 12(4):. PubMed ID: 36831289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter.
    Matsuoka Y; Vila M; Lincoln S; McCormack A; Picciano M; LaFrancois J; Yu X; Dickson D; Langston WJ; McGowan E; Farrer M; Hardy J; Duff K; Przedborski S; Di Monte DA
    Neurobiol Dis; 2001 Jun; 8(3):535-9. PubMed ID: 11442360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Drosophila model of Parkinson's disease.
    Feany MB; Bender WW
    Nature; 2000 Mar; 404(6776):394-8. PubMed ID: 10746727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Propagation of pathological α-synuclein in marmoset brain.
    Shimozawa A; Ono M; Takahara D; Tarutani A; Imura S; Masuda-Suzukake M; Higuchi M; Yanai K; Hisanaga SI; Hasegawa M
    Acta Neuropathol Commun; 2017 Feb; 5(1):12. PubMed ID: 28148299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
    Olanow CW; Brundin P
    Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mice lacking alpha-synuclein are resistant to mitochondrial toxins.
    Klivenyi P; Siwek D; Gardian G; Yang L; Starkov A; Cleren C; Ferrante RJ; Kowall NW; Abeliovich A; Beal MF
    Neurobiol Dis; 2006 Mar; 21(3):541-8. PubMed ID: 16298531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain.
    Higashi S; Biskup S; West AB; Trinkaus D; Dawson VL; Faull RL; Waldvogel HJ; Arai H; Dawson TM; Moore DJ; Emson PC
    Brain Res; 2007 Jun; 1155():208-19. PubMed ID: 17512502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. alpha-Synuclein- and MPTP-generated rodent models of Parkinson's disease and the study of extracellular striatal dopamine dynamics: a microdialysis approach.
    Bazzu G; Calia G; Puggioni G; Spissu Y; Rocchitta G; Debetto P; Grigoletto J; Zusso M; Migheli R; Serra PA; Desole MS; Miele E
    CNS Neurol Disord Drug Targets; 2010 Aug; 9(4):482-90. PubMed ID: 20522009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experimental models of Parkinson's disease.
    Beal MF
    Nat Rev Neurosci; 2001 May; 2(5):325-34. PubMed ID: 11331916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurotoxin-Induced Rodent Models of Parkinson's Disease: Benefits and Drawbacks.
    El-Gamal M; Salama M; Collins-Praino LE; Baetu I; Fathalla AM; Soliman AM; Mohamed W; Moustafa AA
    Neurotox Res; 2021 Jun; 39(3):897-923. PubMed ID: 33765237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.